Issue 5, Volume 128

Cover Figure: Resolving the role of meizothrombin in hemostasis. See the article by Shaw et al.

WASHINGTON, August 4, 2016 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

mTORC1 promotes aging-related venous thrombosis in mice via elevation of platelet volume and activation
In a conceptually fascinating plenary paper, Yang et al shed light on the potential mechanistic connection between platelets and increased risk of venous thrombosis with age. Further, they provide evidence for a novel role of the mTOR system in platelets.

FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease
Schneider et al present studies on the critical role of FBXO11 in BCL6 regulation and maintaining normal function of the germinal center (GC) in B-cell maturation. They furnish the first in vivo evidence that FBXO11 inactivation leads not only to abnormal GC formation but also to lymphoma and lymphoproliferative disease.

Immunoregulatory roles of versican proteolysis in the myeloma microenvironment
Hope et al present their pioneering studies on the functional role of versican/versikine in myeloma and demonstrate the differential influence of versican and its proteolytic derivate, versikine, on the immune system. Their discovery opens a new avenue for adjuvant immunotherapies with T-cell epitope peptide vaccination, chimeric antigen receptor (CAR), and other T-cell therapies in myeloma.

BLVRB redox mutation defines heme degradation in a metabolic pathway of enhanced thrombopoiesis in humans
Wu et al report the discovery of a novel nonsynonymous loss-of-function gene mutation in BLVRB (BLVRB S111L) that correlates with thrombocytosis in essential thrombocythemia and reactive thrombocytosis.

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A
Mahlangu and colleagues present the first major report of the clinical use and effectiveness of a novel modified factor VIII (FVIII) molecule produced by covalently linking the FVIII heavy and light chains in patients with severe hemophilia A.

Setdb1 maintains hematopoietic stem and progenitor cells by restricting the ectopic activation of nonhematopoietic genes
Koide and colleagues identify the H3K9 methyltransferase Setdb1 as a new player in the complex process of epigenetic regulation of hematopoietic stem cell behavior.

Limiting prothrombin activation to meizothrombin is compatible with survival but significantly alters hemostasis in mice
Shaw et al generated a novel genetically modified mouse that expresses a variant of prothrombin that can be cleaved only into meizothrombin, a key intermediate product in the conversion of prothrombin to thrombin. This variant is associated with significant hemostatic consequences. The mouse model will be important in resolving the roles of meizothrombin in hemostasis in vivo.

Mechanisms of platelet-mediated liver regeneration
In a timely Blood Spotlight review, Lisman and Porte present a critical discussion on various relevant aspects of the role of platelets in liver regeneration.

This week's complete table of contents

Why Submit to Blood?

Join the "This Week in Blood" mailing list by filling out the form below and clicking Subscribe!
*Email Address:
*First Name:
*Last Name:


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.